IN THE NEWS

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

March 13th, 2020|

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA Progeria NDA Submission Complete by End of March 2020 Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif., March 13, 2020 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the fourth quarter and full [...]

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

January 7th, 2020|

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer Launch Preparation Underway for Lonafarnib in Progeria Market Development Activities Advancing for HDV Program PALO ALTO, Calif., January 7, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Eldon Mayer as Executive Vice President and Chief Commercial Officer.  Mr. Mayer is a [...]

Eiger Updates on 2019 Progress and 2020 Milestones Expected

January 6th, 2020|

Eiger Updates on 2019 Progress and 2020 Milestones Expected Progeria Rolling NDA Planned for Completion in 1Q 2020 HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020 Commercial Focus on Progeria Launch Preparation and HDV Market Building Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020 PALO ALTO, Calif., January 6, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and [...]